Pathfinders in Biopharma
RBC Capital Markets
Subscribe
Perspectives from the cutting edge of biotech and pharma.
The fast-changing world of biopharma places a premium on trusted market insights from industry experts who can turn change into a competitive advantage. Stay ahead of the curve with our latest podcast series.
Lead today. Define tomorrow.
Available episodes
Newest first
Oldest first
May 22, 2023
Global Blood Therapeutics Commitment to Sickle-Cell Innovation
In this rebroadcast episode, we flash back to a previous interview with Dr. Ted W. Love, President and CEO of Global Blood Therapeutics (GBT). Dr. Love spoke with our biotechnology analyst Gregory Renza about GBT’s mission-driven culture which led to the development of Oxbryta, the company’s breakthrough sickle-cell treatment, as well as the specific challenges the company faced in tackling a rare orphan disease.
GBT was acquired by Pfizer in October 2022, reinforcing their commitment to sick cell disease and continuing to build on their 30-year legacy in the rare hematology space.
playlist_add
Apr 13, 2023
Is This the Breakthrough Moment for Genetic Medicine?
Genetic medicine is poised to unlock more value for patients and investors due to disruptive technologies like mRNA, siRNA and gene editing. With an estimated 27 genetic medicines already approved, RBC’s biotechnology analyst Luca Issi explains how these technologies could be used next, and why companies able to combine the right choice of intervention with strong execution may stand to benefit most.
playlist_add
Jan 26, 2023
The Hidden Revolution Set to Turn US Healthcare on its Head
In the latest episode of Pathfinders, our Healthcare technology analyst Sean Dodge explores a quiet but accelerating revolution in the way US healthcare works – and the new breed of companies poised to benefit.
playlist_add
Dec 13, 2022
The Big Picture for Biotech
In this latest episode, our head of biotech research Brian Abrahams shares a big picture analysis of the industry, outlining the long-term disruptions and opportunities ahead for biotech.
playlist_add
Nov 22, 2022
Why Biopharma Investment Requires a Different Mindset
In the latest episode of Pathfinders, Noël Brown, Head of US Biotechnology Investment Banking at RBC Capital Markets, reveals why he’s feeling optimistic about M&A in biopharma and how leading in biotech investment and corporates needs visionary long-term thinking.
playlist_add
Oct 3, 2022
The Optimism Behind the Biopharma Market
In this episode, Dr. Chen Yu, Founder and Managing Partner at TCG X and Noël Brown, Head of U.S. Biotechnology Investment Banking at RBC Capital Markets, discuss why they remain optimistic about biotech and what’s happening behind the scenes in public and private markets.
playlist_add
Mar 21, 2022
Biotech Investors: How to Find Value in a Bear Market
How are top investors navigating the longest biotech bear market in almost 20 years? RBC Capital Markets Healthcare Desk Sector Strategist Chris McCarthy talks to HealthCor’s Ben Snedeker and Omega Funds founder Otello Stampacchia to find out.
playlist_add
Dec 8, 2021
A call to action: Global Blood Therapeutics on tackling orphan disease
What does it take to tackle the most perplexing orphan diseases? Ted W. Love, M.D., President and CEO, Global Blood Therapeutics (GBT), speaks with RBC Capital Markets’ Senior Biotechnology Analyst Gregory Renza, M.D., about having a mission and the drive to succeed on this episode of Pathfinders.
playlist_add
Oct 28, 2021
Ionis: Raising The Bar For ESG
In this episode of Pathfinders, Luca Issi, Senior Biotech Analyst at RBC Capital Markets, speaks with Beth Hougen, CFO of Ionis – a leading innovator in the development of antisense medicines and RNA-targeted therapeutics – to find out how the firm is embedding ESG into its vision, strategy and performance.
playlist_add
Sep 30, 2021
Biotech and Big Pharma: Blueprint for Successful Partnership
As biotech firms and large pharma companies find new synergies to bring new treatments to market together, Noël Brown, Managing Director and Head of US Biotechnology Investment Banking at RBC Capital Markets, interviews pharma industry veteran, now Biopharma Managing Director, Greg Wiederrecht on what it takes to ensure a strategic partnership not only survives, but thrives.
playlist_add
May 4, 2021
What’s Material in ESG for Biopharma Firms?
For biopharma companies, ESG commitments can look considerably different from other sectors. We spoke with the team of ESG leads at Gilead Sciences to understand the five key components driving its ESG strategy, how it’s evolved and how it impacts their business.
playlist_add
Apr 26, 2021
Inside Track: Behind the Scenes of a Major Biotech SPAC
RBC Capital Markets’ Noël Brown, Head of US Biotech Investment Banking, goes behind the scenes of one of the biggest biotech SPAC deals of the year with NuvationBio Founder and CEO, Dr. David Hung and Omega Funds Partner and President of its Omega Alpha SPAC, Michelle Doig. These two industry leaders at the cutting edge of biotech innovation and venture capital share how they brought NuvationBio’s public market vision to fruition on the latest episode of RBC’s Pathfinders podcast.
playlist_add
Mar 12, 2021
Biotech SPACs: A new route to going public
As more firms and investors look to SPACs as an IPO alternative, will this change the way biotech companies access public markets long-term? Our investment banking team goes inside the SPAC boom to explain what companies need to know before choosing their path to going public.
playlist_add
Dec 21, 2020
5AM Ventures: Fueling the Next Generation of Innovators
In this episode of Pathfinders, Brian Abrahams, Managing Director and Co-Head of Biotechnology Equity Research at RBC Capital Markets speaks with Andy Schwab, Co-Founder and Managing Partner at 5AM Ventures.Key Points
* Prescription Digital Therapeutics will be vital to future treatment
* Unlocking microbiome could lead to better disease management
playlist_add
Dec 21, 2020
Vida Ventures: Powering Breakthroughs in Biopharma
Luca Issi, Senior Biotechnology Research Analyst at RBC Capital Markets, discusses the art of building biopharma breakthroughs with Arjun Goyal, Co-Founder and Managing Director of Vida Ventures.Key Points
* Maturation of the industry is increasing innovation and capital inflows
* Strong science, management and investors can keep the IPO window open
playlist_add
Dec 10, 2020
Biotech IPOs: Navigating the New Landscape
Even in a boom, many biotech executives may be unprepared for the risks involved in undertaking an IPO. Noël Brown and Tim Papp, Managing Directors focused on biotechnology in our Global Healthcare Investment Banking and Jason Levitz, Head of Healthcare Equity Capital Markets at RBC Capital Markets discuss the right steps to take, and the pitfalls to avoid, in today’s markets.
playlist_add
Dec 1, 2020
Biotech IPOs: New Steps to Success on the Road to Going Public
In our launch edition of Pathfinders, we look at the best practices to follow on the road to IPO and the new predictive factors for success in today’s buoyant biopharma markets.
playlist_add